Other Issues

Browse Other Issues Content

This page serves as a central resource for the latest updates on tariffs and trade policy announcements from the White House that may impact our industry. Below is timely information including official statements and guidance for members, media, and other stakeholders navigating changes in trade and supply chain policy. We are committed to keeping you informed and engaged as we advocate for access, affordability, and innovation.

Child-resistant packaging is used to reduce the risk of poisoning in children via the ingestion of potentially hazardous items including certain prescription and OTC medications, pesticides, and household chemicals.

CHPA is uniquely positioned to provide access to OTC medicines and dietary supplements in nearly every category that can be donated and customized to the needs of underserved communities. Our product donation initiative is an ongoing effort to support these communities. So far, CHPA member companies have donated 70,000 products to people in need.

Rather than legislate additional state-level extended producer responsibility mandates aimed at packaging, lawmakers should support manufacturers already innovating sustainability solutions within the FDA's extensive regulatory framework that balances both environmental considerations and patient safety needs.

Lawmakers should support the centralized progress made on ingredient evaluation, labeling, and packaging protections by specialized national children’s health agencies instead of allowing jurisdiction confusion that ultimately hinders healthcare advancement for all ages.

Regulation of Dietary Supplements covers marketing, manufacturing, labeling, and advertising enforced by FDA and the Federal Trade Commission. See these FAQs to learn more.

FDA Announcement of a proposed safety-based Administrative Order that proposes to add a skin allergy warning to labeling requirements for acetaminophen-containing drug products.

The bipartisan federal Combat Meth Epidemic Act strikes the proper policy balance between restricting pseudoephedrine access for illicit use without unduly burdening consumers seeking safe, effective cold relief. Therefore, state legislators should refrain from overriding federal guidelines requiring prescriptions for these legitimate over-the-counter medications.

Filter Results